Month: September 2026

Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new European LIFE project dedicated to tackling one of today’s most persistent environmental challenges: PFAS contamination. The consortium will demonstrate a more sustainable, scalable and cost-effective approach to permanently degrading PFAS across different contaminated matrices.

PFAS, often referred to as “forever chemicals”, are highly persistent, mobile and bioaccumulative substances found in soils, water, ecosystems and waste streams. Current remediation approaches often rely on containment, landfill or incineration, which can be costly, energy-intensive and may not fully eliminate contamination.

An integrated approach spanning the entire treatment chain
LIFEDESTINY (DEmonstration of Sustainable Technologies for INnovative PFAS remediation strategy) aims to prove the feasibility of an integrated treatment process covering the full PFAS remediation chain, from the sourcing and preparation of contaminated materials to PFAS concentration, destruction, analytical validation, neutralisation and potential reuse of treatment residues. The project will address a broad range of liquid and solid waste streams, including industrial wastewater, contaminated soil, sludge and spent granular activated carbon. By combining complementary concentration and destruction technologies, the consortium aims to develop a scalable and energy-efficient alternative to conventional PFAS containment, landfilling and incineration.

A Belgian consortium bringing together the entire value chain
As coordinator, IBA will contribute with its advanced electron beam technology, based on its Rhodotron^® accelerator, to support the destruction of PFAS in contaminated liquid and solid waste streams. This technology will be combined with complementary expertise from project partners.

Alongside IBA, Haemers Technologies brings one of the project’s two PFAS destruction routes for solid matrices, treating contaminated soils and sludges through Krysalis^® thermal desorption while enabling material reuse. NOVOBIOM will develop biosurfactant-based solutions to extract and concentrate PFAS from soil and sludge. DEME Environnement and BESIX Environment will contribute industrial waste streams, remediation expertise, process integration and scale-up capabilities. CEBEDEAU will concentrate PFAS from industrial wastewater and will perform the validation needed to assess treatment efficiency and residue safety. Carmeuse Europe will develop solutions to neutralise fluoride-containing effluents and explore the reuse of treated by-products, while District Cleantech will support stakeholder engagement, dissemination and the project’s pathway towards a future industrial PFAS treatment hub.

The four-year project brings together a Belgian consortium covering the full PFAS treatment value chain, from contaminated waste sourcing and analytical validation to remediation, destruction, neutralisation, reuse and dissemination. Running from 1 September 2026 to 31 August 2030, LIFEDESTINY combines advanced concentration and destruction technologies in an integrated treatment process designed to reduce energy use, CO₂ emissions and hazardous residues compared with conventional approaches.

Catherine Vandenborre, Chief Ventures & Corporate Officer of IBA commented, “LIFEDESTINY complements other initiatives in which IBA is involved to address PFAS contamination and reinforces our ambition to tackle PFAS destruction in a holistic way. By bringing together complementary technologies and expertise across the full treatment value chain, the project reflects IBA’s mission to protect, enhance and save lives — extending the impact of our accelerator expertise to one of today’s most pressing environmental and public health challenges.”

60% European funding
LIFEDESTINY has total eligible project costs of €4,428,018.45 and a maximum EU grant amount of €2,651,675.07, representing a 60% funding rate. Beyond the demonstration phase, the project’s long-term ambition is to lay the foundations for a full-scale PFAS treatment centre or hub capable of industrial-scale deployment.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Climate, Infrastructure and Environment Executive Agency (CINEA). Neither the European Union nor the granting authority can be held responsible for them.

***

 

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

Thomas Pevenage Head of Investor Relations +32 10 475 890 investorrelations@iba-group.com

Nathalie van Ypersele Head of Communication and Sustainability Daniel Ernult Corporate Communication Manager +32 10 475 890 communication@iba-group.com

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, September 25, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s rationalization of its research and development activities and the announcement of the planned merger of Indivior’s parent company with Supernus Pharmaceuticals, Inc.

“These GABAB PAM assets reflect years of world-class research in allosteric modulation and build on a biological approach clinically validated by baclofen,” said Tim Dyer, CEO of Addex Therapeutics. “By regaining the rights to the development candidate selected by Indivior, we now have the flexibility to advance our broader GABAB PAM portfolio independently. This includes the returned candidate for substance use disorders and our proprietary candidate in development for chronic cough. We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering.”

The termination of the collaboration with Indivior provides Addex with full ownership of the returned development candidate and the freedom to pursue therapeutic indications beyond those originally contemplated under the agreement. Combined with Addex’s wholly owned GABAB PAM program for chronic cough, the returned asset gives the company one of the broadest portfolios targeting GABAB receptor biology. The portfolio may have potential applications across substance use disorders, chronic cough, pain, overactive bladder, neurodevelopmental disorders, and other conditions in which modulation of GABAB signaling has demonstrated therapeutic promise.

About GABAB activation
GABA is the main inhibitory neurotransmitter in the central and peripheral nervous systems and acts through two major receptor classes: the ionotropic GABAA receptor and the metabotropic GABAB receptor. GABAB receptors are widely expressed throughout the nervous system and play an important role in regulating neuronal excitability and neurotransmission.

The therapeutic potential of GABAB receptor activation has been clinically demonstrated with baclofen, a selective GABAB receptor agonist that binds to the orthosteric GABA binding site. Baclofen is approved for the treatment of spasticity, including spasticity associated with multiple sclerosis and spinal cord injury. It has also been clinically investigated and used off-label across a broader range of neurological, neuropsychiatric disorders and other conditions including alcohol use disorder and alcohol withdrawal, cocaine use disorder, gastroesophageal reflux disease, and reflux-associated chronic cough.

Although baclofen has demonstrated the therapeutic potential of GABAB receptor activation, its broader use is constrained by aspects of its pharmacological and pharmacokinetics profile. These include sedation and other central nervous system side effects, as well as the potential for reduced efficacy during chronic treatment.

GABAB PAMs offer an alternative approach to enhancing GABAB signaling. Rather than binding to the orthosteric GABA-binding site, PAMs bind to a distinct allosteric site and enhance the receptor’s response to endogenous GABA. This mechanism is intended to preserve the physiological and activity-dependent nature of GABAB receptor signaling. By enhancing the effects of endogenous GABA, GABAB PAMs have the potential to provide greater pathway selectivity, improved tolerability and a reduced propensity for tolerance compared with direct orthosteric agonism. GABAB PAMs therefore represent a promising therapeutic approach for neurological, neuropsychiatric and other disorders in which modulation of inhibitory neurotransmission may provide clinical benefit.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.  

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.

Contacts:

Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com

Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. 

WISeKey and OISTE.ORG Expand Post-Quantum Root of Trust to Secure the Quantum and AI Era

Quantum-safe Root of Trust designed to provide verifiable identities for AI models, agents, devices and humans, creating a cryptographic foundation for trusted AI

Geneva, Switzerland, September 25, 2026 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, in collaboration with the OISTE.ORG Foundation, announced the expansion of its Quantum Root Key initiative into a Post-Quantum Cryptography (“PQC”) Root of Trust architecture for AI systems, autonomous agents, connected devices and human operators.

The Quantum Root Key was originally generated to address one of the most significant cybersecurity challenges of the coming decade: the potential ability of sufficiently powerful quantum computers to compromise widely deployed public-key cryptographic systems.

However, the rapid development of increasingly autonomous AI systems introduces another fundamental challenge:

How do humans, machines and other AI systems know that an AI model or AI agent is authentic, authorized and operating with trusted software, data and instructions?

WISeKey and OISTE believe that the answer begins with a cryptographically verifiable Root of Trust.

From Root of Trust to Trusted AI

The same Public Key Infrastructure principles that have authenticated websites, devices and digital identities for decades can be extended to support machine-verifiable trust for AI.

Under this architecture, the OISTE/WISeKey Root of Trust can act as the cryptographic trust anchor from which identities and credentials may be issued to AI models, AI agents, devices, organizations and authorized human operators.

Rather than simply trusting an AI because it claims to be a particular model or agent, systems could cryptographically verify its identity and provenance.

This creates a potential chain of trust: Post-Quantum Root of Trust → Organization → AI Model → AI Agent → Device → Transaction

Each element can carry a cryptographically verifiable identity derived from the trusted root.

Securing AI Through Cryptographic Identity

The Root of Trust architecture can support several critical functions required for trusted AI.

• AI Model Identity. AI models can receive cryptographic identities allowing systems to verify which model they are communicating with and whether that identity was issued by an authorized organization.
• Model Integrity and Provenance. Cryptographic signatures and hashes can help verify that model binaries, weights, software components and approved configurations have not been modified since their authorized release.
• AI Agent Authentication. Autonomous agents can authenticate themselves before accessing systems, APIs, financial services, IoT infrastructure or other AI agents.
• Human-to-AI Authorization. Human operators can use trusted digital identities and certificates to establish who is authorized to instruct, modify, deploy or terminate an AI agent.
• AI-to-AI Trust. As autonomous agents increasingly transact with each other, cryptographic credentials can allow one agent to verify the identity and authorization of another before exchanging information or executing transactions.
• Signed AI Actions. High-impact AI actions could be digitally signed, creating evidence of which agent initiated an action, under which identity and authorization.
• Trusted Audit Trails. Signed events can be recorded in tamper-evident or immutable audit systems, creating traceability across the AI lifecycle.

This introduces an important principle for the AI economy: Every AI should have an identity. Every AI action should be attributable. Every critical AI interaction should be verifiable.

Post-Quantum Security at the Foundation

The Root of Trust uses Post-Quantum Cryptography designed to remain secure against both conventional and future quantum attacks.

The architecture incorporates NIST-standardized PQC algorithms including ML-DSA and ML-KEM, together with additional quantum-resistant cryptographic technologies as appropriate to each deployment.

These technologies can be integrated into WISeKey’s trusted infrastructure and Post-Quantum PKI platform, anchoring cryptographic operations within tamper-resistant environments including Hardware Security Modules (HSMs), Trusted Platform Modules (TPMs) and secure semiconductor elements.

The objective is to ensure that the identity infrastructure securing tomorrow’s AI systems does not depend on cryptography that could subsequently become vulnerable to quantum computing.

Hardware Root of Trust: From Cloud AI to the Edge

A critical component of the architecture is connecting digital trust to hardware. Through its subsidiary, SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), which focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, WISeKey’s semiconductor technology ecosystem can extend the Root of Trust into secure elements, TPMs and post-quantum semiconductor architectures.

This enables an AI workload running on a server, robot, vehicle, industrial controller, satellite or IoT device to establish a cryptographically verifiable relationship between: hardware → firmware → operating environment → AI model → AI agent → authorized user

Such hardware-backed attestation can make it significantly harder for attackers to impersonate legitimate AI agents or silently replace authorized software and models.

A Trust Architecture for AI Supervising AI

The Root of Trust can also become an important component of WISeKey and OISTE’s emerging HUMAN-AI-T framework.

As AI models become more powerful, one potential safety architecture is to use specialized AI systems to supervise the actions of other AI systems while preserving ultimate human governance.

Within this model, a supervisory AI would not merely monitor another model. Both systems would possess independently verifiable cryptographic identities.

The architecture could operate as: OISTE Post-Quantum Root of Trust →Trusted Human Governance → Authenticated AI Supervisor → Authenticated AI Models and Agents → Cryptographically Authorized Actions → Tamper-Evident Audit Trail → Human Escalation / Intervention

The Root of Trust therefore does not attempt to determine whether an AI is “good” or “bad.” Instead, it provides something more fundamental: verifiable identity, integrity, authorization and accountability.

These mechanisms can complement model-level AI safety controls by providing a security layer underneath them.

From “Trust Me” AI to “Verify Me” AI

Today’s AI ecosystem largely depends on organizational and platform trust. Users often cannot independently determine which model generated an output, whether the model was modified, what agent initiated an action, or whether an instruction came from an authorized source.

WISeKey and OISTE’s approach is designed to move toward a “Verify Me” architecture.

An AI system could potentially present a cryptographically verifiable credential demonstrating:

• Who created me.
• Which organization authorized me.
• Which model and version I am running.
• Whether my software environment has been altered.
• What permissions I possess.
• Who authorized the action I am requesting.
• And whether my credentials remain valid.

This cryptographic trust layer could become increasingly important as billions of autonomous AI agents begin communicating, negotiating and transacting across digital networks.

Protecting Critical Infrastructure

The combined PQC and AI Root of Trust architecture is particularly relevant for sectors where autonomous AI decisions could have physical, financial or national-security consequences, including financial services, healthcare, telecommunications, defense, energy, industrial systems, satellites, smart cities, connected vehicles and IoT infrastructure.

Post-Quantum certificates issued through the platform maintain concepts familiar to conventional PKI, including Root and Intermediate Certificate Authorities, defined Key Usages, Certificate Revocation Lists and certificate status mechanisms, while incorporating quantum-resistant cryptographic algorithms.

Building the Trust Layer for the Intelligent Internet

Carlos Moreira, Founder and CEO of WISeKey, stated: “AI is rapidly moving from generating information to taking autonomous actions. In that environment, identity becomes fundamental. Before an AI agent can access infrastructure, communicate with another AI or execute a transaction, we need to know cryptographically who that agent is, who authorized it and whether it has been modified. Our Post-Quantum Root of Trust creates the foundation for this new trust architecture. The objective is simple: AI should not have to be blindly trusted. AI should be cryptographically verifiable. By combining OISTE’s global Root of Trust, WISeKey’s PKI infrastructure and SEALSQ’s secure semiconductor technologies, we believe we can extend digital trust from humans and connected devices to AI models and autonomous agents.”

The convergence of Artificial Intelligence and Quantum Computing represents both an extraordinary technological opportunity and a fundamental cybersecurity challenge.

WISeKey and OISTE believe that the infrastructure protecting this new digital environment must therefore evolve from simply securing communications to establishing identity, provenance, authorization and accountability across humans, machines and AI.

The objective is to create a global trust layer capable of supporting the next generation of the Internet:

• Humans trusting AI.
• AI trusting humans.
• AI trusting AI.
• All anchored in a Post-Quantum Root of Trust.

About WISeKey

WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA, which specializes in RoT and PKI solutions for secure authentication and identification in IoT, blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and houses the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication contains forward-looking statements concerning WISeKey International Holding Ltd and/or its subsidiaries (collectively, “WISeKey,” “our” or “us”) and its businesses. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that could cause WISeKey’s actual results, financial condition, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include: our ability to convert our pipeline into actual sales; the ability to realize WISeKey’s anticipated growth strategies and profitability; the development of post-quantum cryptography products and the potential market for such products; WISeKey’s plans for global customer base expansion; the expansion of the WISeSat project and the QSOC initiative; the timing and expected revenues from the commercial deployment of the QS7001 quantum-resistant semiconductor; the sufficiency of cash to meet liquidity needs; WISeKey’s ability to attract and retain customers; changes in economic conditions; market demand and semiconductor industry conditions; and the risks discussed in WISeKey’s filings with the SEC. WISeKey is providing this communication as of this date and does not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

Statements regarding our business pipeline are based on management’s current estimates of potential revenue opportunities and do not represent backlog or contracted revenue. Pipeline conversion is subject to numerous factors including customer validation, technical integration requirements, certification timelines, and market conditions. There can be no assurance that pipeline opportunities will convert to actual sales or that such conversion will occur within anticipated timeframes.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeKey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com